PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
This research is Trending!
March 21, 2026Circulation Journal1 citationsOpen Access

Apple Watch-Guided Anticoagulation After Atrial Fibrillation Ablation　― The Up to AF Trial ―

ASA SunagaNTNobuaki TanakaYEYasuyuki Egami

Key Result

Apple Watch-guided event-triggered anticoagulation reduced DOAC exposure by 94.6% compared with continuous anticoagulation in post-ablation atrial fibrillation patients, with no thromboembolic events.

Key Points

  • To assess the effectiveness of an Apple Watch-guided anticoagulation strategy for patients after atrial fibrillation ablation.
  • Evaluated the use of Apple Watch for real-time detection of atrial fibrillation events.
  • Implemented an event-triggered anticoagulation strategy based on smartwatch data.
  • Monitored changes in direct oral anticoagulant (DOAC) use according to AF occurrence.
  • Demonstrated effective adjustment of DOAC use based on real-time AF detection.
  • Showed improvements in anticoagulation management compared to standard methods.

Structured PICO

Does an Apple Watch-guided event-triggered anticoagulation strategy reduce DOAC exposure in postablation atrial fibrillation patients with a CHA2DS2-VASc score ≤3?

P
Population
Adults aged ≥22 years with no atrial fibrillation recurrence for at least 3 months after catheter ablation, currently taking a DOAC, with a CHA2DS2-VASc score ≤3.
I
Intervention
Apple Watch-guided event-triggered anticoagulation strategy (DOAC discontinued on Day 31 if no AF detected, and resumed if an Apple Watch notification or ECG confirmed AF).
O
Outcome
Percentage reduction in total DOAC days between Days 31 and 360, relative to a conventional strategy of continuous anticoagulation.surrogate

An Apple Watch-guided event-triggered anticoagulation strategy safely and markedly reduced DOAC exposure by 94.6% in postablation AF patients with low-to-moderate stroke risk.

Main Result

Effect estimate: 94.6% reduction (95% CI 89.8-98.4)

Absolute Event Rate: 5.4% vs 100%

Limitations

  • Apple Watch does not issue notifications during exercise
  • Round-the-clock heart rate monitoring is not feasible because the device must be removed for charging
  • Precise daily wear time could not be determined
  • Suboptimal protocol adherence in some episodes
  • Single-arm study design
  • Limited sample size
  • Low baseline thromboembolic risk

Abstract

Background: Continuous anticoagulation guided by the CHA2DS2-VASc score is standard for atrial fibrillation (AF) but does not reflect real-time AF occurrence. We evaluated an Apple Watch-guided event-triggered anticoagulation strategy that adjusts direct oral anticoagulant (DOAC) use according to smartwatch detection.

Ask AI
Helpful
Bookmark
Share
View Full Paper
Trending Research#5 this week

The Up to AF trial demonstrates that an Apple Watch-guided strategy significantly reduces DOAC exposure after AF ablation without thromboembolic events, sparking debate on wearable-driven therapy.

Social attention
88
Preprint velocity
0
News coverage
75
Conference
0
Expert commentary
0

Cite This Study

Sunaga et al. (2026) studied Atrial fibrillation post-ablation (n=54). Apple Watch-guided event-triggered anticoagulation vs. Continuous anticoagulation was evaluated on Percentage reduction in total DOAC days between Days 31 and 360 (94.6% reduction, 95% CI 89.8-98.4). Apple Watch-guided event-triggered anticoagulation reduced DOAC exposure by 94.6% compared with continuous anticoagulation in post-ablation atrial fibrillation patients, with no thromboembolic events.

synapsesocial.com/papers/69be371c6e48c4981c67679bhttps://doi.org/10.1253/circj.cj-26-0066
Ask AI
Helpful
Bookmark
Share
View Full Paper